Shigeta et al., 2020 - Google Patents
Dual programmed death receptor‐1 and vascular endothelial growth factor receptor‐2 blockade promotes vascular normalization and enhances antitumor immune …Shigeta et al., 2020
View PDF- Document ID
- 13031207879287195389
- Author
- Shigeta K
- Datta M
- Hato T
- Kitahara S
- Chen I
- Matsui A
- Kikuchi H
- Mamessier E
- Aoki S
- Ramjiawan R
- Ochiai H
- Bardeesy N
- Huang P
- Cobbold M
- Zhu A
- Jain R
- Duda D
- Publication year
- Publication venue
- Hepatology
External Links
Snippet
Background and Aims Activation of the antitumor immune response using programmed death receptor‐1 (PD‐1) blockade showed benefit only in a fraction of patients with hepatocellular carcinoma (HCC). Combining PD‐1 blockade with antiangiogenesis has …
- 206010073071 Hepatocellular carcinoma 0 title abstract description 109
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shigeta et al. | Dual programmed death receptor‐1 and vascular endothelial growth factor receptor‐2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma | |
| Shigeta et al. | Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma | |
| Tang et al. | Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy | |
| Li et al. | Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1 | |
| Chen et al. | CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice | |
| JP2022065034A (en) | Chimeric pox virus compositions and uses thereof | |
| TW201722477A (en) | Methods of treating solid or lymphatic tumors by combination therapy | |
| TW201032796A (en) | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor | |
| Fu et al. | Combination foretinib and anti-PD-1 antibody immunotherapy for colorectal carcinoma | |
| Shigeta et al. | Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC | |
| JP2011528326A (en) | Compositions comprising in vitro expanded T lymphocytes and angiogenesis inhibitors suitable for cancer treatment | |
| Zhang et al. | Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma | |
| WO2018039332A1 (en) | Immunoswitch nanoparticles for reprogrammed t cell responses | |
| WO2015157299A2 (en) | Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells | |
| Gryziak et al. | The immune landscape of hepatocellular carcinoma-where we are? | |
| Li et al. | PD-1 checkpoint blockade in combination with an mTOR inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1 | |
| JP2022511881A (en) | Manipulated flagellin-derived compositions and uses | |
| Xing et al. | Preliminary analysis of stem cell-like cells in human neuroblastoma | |
| Wilczak et al. | Melanoma-derived extracellular vesicles transfer proangiogenic factors | |
| US20220125770A1 (en) | Combination therapy of alk-positive neoplasia | |
| US20220025036A1 (en) | Use of il-1beta binding antibodies | |
| Morita et al. | Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models | |
| Li et al. | Efficacy of bispecific antibody targeting EpCAM and CD3 for immunotherapy in ovarian cancer ascites: an experimental study | |
| JP2021523359A (en) | Patient selection for combination therapy | |
| Ma et al. | Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors |